AzTrials
AzTrials

Low Back PainPhase 4NCT01843660

An Efficacy and Safety Study of Tramadol Hydrochloride-Paracetamol in Treatment of Moderate to Severe Acute Neck-Shoulder Pain and Low Back Pain

A Phase 4 study testing Tramadol HCl-Paracetamol in people with Low Back Pain and Shoulder Pain, run by Xian-Janssen Pharmaceutical Ltd..

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study is to evaluate the efficacy and safety of tramadol hydrochloride-paracetamol tablets in treatment of moderate (medium level of seriousness) to severe (very serious) acute neck, shoulder and low back pain in orthopedics (pertaining to the bones) outpatient or emergency setting. Read more about this study

Who is it for?
Ages 18 to 65 years
Conditions the study is for
Low Back Pain, Shoulder Pain, Neck Pain
What is being tested?
Tramadol HCl-Paracetamol
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
1,059 participants
Where
No sites listed yet
Study dates
Sep 2007to May 2008
Phase
Phase 4
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Intermittent or persistent pain for less than 3 months, required analgesic therapy, orthopedic surgery and emergency call participants suffering with severe neck, shoulder, low back pain or chronic neck, shoulder, lower back pain, acute (a quick and severe form of illness in its early stage) exacerbation pain
  • Pain intensity to be assessed using Numerical Rating Scale (NRS), NRS score more than or equal to 4 (from 0 to 10, 0 = no pain, 10 = extreme pain)
  • During normal pain and stable feeling, can study pain assessment methods and can fill in pain control diary
  • Be willing to participate in the study and must give written informed consent

Who cannot join

  • Have used strong opium kind of medication 7 days prior to the enrolment
  • Have severe mental disease or using antipsychotic (agent that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect) medication for medical treatment
  • Drug abuse/dependence, or chronic alcohol abuse/depend on history
  • Pregnant or lactating women
  • Unable to tolerate tramadol or any failed treatment in past by using tramadol
  • Comparatively more severe pain in other parts of the body than that of the pain mentioned in the research

About this study

Official title: The Clinical Efficacy and Safety Study of Tramadol Hydrochloride - Paracetamol Tablets in the Treatment of Moderate to Severe Acute Neck-shoulder Pain and Low Back Pain in Orthopaedics Outpatient or Emergency Setting

The purpose of this study is to evaluate the efficacy and safety of tramadol hydrochloride-paracetamol tablets in treatment of moderate (medium level of seriousness) to severe (very serious) acute neck, shoulder and low back pain in orthopedics (pertaining to the bones) outpatient or emergency setting.

Read the detailed description

This is an open-label (all people know the identity of the intervention), non-randomized, multi-center (when more than one hospital or medical school team work on a medical research study) and prospective (study following participants forward in time) study of tramadol hydrochloride-paracetamol tablets. Participants will receive 1 to 2 tablets of tramadol hydrochloride-paracetamol orally once daily (each tablet containing tramadol 37.5 milligram [mg] and paracetamol 325mg). Participants may be given the additional dose according to the clinical requirement. The total treatment duration will be 6 hours. The total study duration will be 4 months. Efficacy will be evaluated primarily by pain intensity and pain relief. Participants will evaluate the pain severity and pain relief at 0.5, 1, 2, 3, 4 and 6 hours respectively after the first dose; and the drug efficacy and overall satisfaction level at the end of 6 hours after the first dose. Participants' safety will be monitored throughout the study.

Being tested
Tramadol HCl-Paracetamol
Keywords
Low back pain, Shoulder pain, Neck pain, Tramadol hydrochloride, Paracetamol
Medical subject headings
Low Back Pain, Shoulder Pain, Neck Pain

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Tramadol HCl-ParacetamolDrug

    Participants will receive 1 to 2 tablets of tramadol HCl-paracetamol orally once daily (each tablet containing tramadol 37.5 milligram [mg] and paracetamol 325mg) for up to a total duration of 6 hours. Additional dose may be given based upon the clinical requirement.

Study groups in NCT01843660
Study groupRoleWhat they receive
Tramadol Hydrochloride (HCl)-ParacetamolExperimentalNot described
Receives: Drug: Tramadol HCl-Paracetamol

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Pain Intensity Score Based on Numeric Rating Scale (NRS) at Hour 0.5

    Pain intensity was measured using NRS (0=painless and 10=most severe pain). Score of 1-3 means mild pain; 4-6 means moderate pain and 7-10 means severe pain.

    Measured: Hour 0.5

  2. Pain Intensity Score Based on Numeric Rating Scale (NRS) at Hour 1

    Pain intensity was measured using NRS (0=painless and 10=most severe pain). Score of 1-3 means mild pain; 4-6 means moderate pain and 7-10 means severe pain.

    Measured: Hour 1

  3. Pain Intensity Score Based on Numeric Rating Scale (NRS) at Hour 2

    Pain intensity was measured using NRS (0=painless and 10=most severe pain). Score of 1-3 means mild pain; 4-6 means moderate pain and 7-10 means severe pain.

    Measured: Hour 2

  4. Pain Intensity Score Based on Numeric Rating Scale (NRS) at Hour 3

    Pain intensity was measured using NRS (0=painless and 10=most severe pain). Score of 1-3 means mild pain; 4-6 means moderate pain and 7-10 means severe pain.

    Measured: Hour 3

  5. Pain Intensity Score Based on Numeric Rating Scale (NRS) at Hour 4

    Pain intensity was measured using NRS (0=painless and 10=most severe pain). Score of 1-3 means mild pain; 4-6 means moderate pain and 7-10 means severe pain.

    Measured: Hour 4

  6. Pain Intensity Score Based on Numeric Rating Scale (NRS) at Hour 6

    Pain intensity was measured using NRS (0=painless and 10=most severe pain). Score of 1-3 means mild pain; 4-6 means moderate pain and 7-10 means severe pain.

    Measured: Hour 6

  7. Number of Participants With Pain Relief Score at Hour 0.5

    Pain relief was measured using 6-point Likert Scale (4=complete, 3=significant/comparatively large, 2=moderate, 1=mild/slight, 0=none, -1=exacerbated/heavier).

    Measured: Hour 0.5

  8. Number of Participants With Pain Relief Score at Hour 1

    Pain relief was measured using 6-point Likert Scale (4=complete, 3=significant/comparatively large, 2=moderate, 1=mild/slight, 0=none, -1=exacerbated/heavier).

    Measured: Hour 1

  9. Number of Participants With Pain Relief Score at Hour 2

    Pain relief was measured using 6-point Likert Scale (4=complete, 3=significant/comparatively large, 2=moderate, 1=mild/slight, 0=none, -1=exacerbated/heavier).

    Measured: Hour 2

  10. Number of Participants With Pain Relief Score at Hour 3

    Pain relief was measured using 6-point Likert Scale (4=complete, 3=significant/comparatively large, 2=moderate, 1=mild/slight, 0=none, -1=exacerbated/heavier).

    Measured: Hour 3

  11. Number of Participants With Pain Relief Score at Hour 4

    Pain relief was measured using 6-point Likert Scale (4=complete, 3=significant/comparatively large, 2=moderate, 1=mild/slight, 0=none, -1=exacerbated/heavier).

    Measured: Hour 4

  12. Number of Participants With Pain Relief Score at Hour 6

    Pain relief was measured using 6-point Likert Scale (4=complete, 3=significant/comparatively large, 2=moderate, 1=mild/slight, 0=none, -1=exacerbated/heavier).

    Measured: Hour 6

Secondary outcomes (3)
  1. Number of Participants Who Required Additional Dosage Administration

    Number of participants who additionally required a second tablet within 2 hours after the first administration of the investigational drug was reported.

    Measured: Baseline up to Hour 2

  2. Number of Participants With Analgesic Satisfaction Score

    Participants evaluated their satisfaction with the analgesic effect of the study drug using a 4-point scale (4=very good, 3=good, 2=average, 1=poor). Number of participants in each category was reported.

    Measured: Hour 6

  3. Number of Participants With Overall Analgesic Satisfaction Score

    Participants and physicians separately evaluated their satisfaction with the analgesic effect of the study drug using a 5-point scale (1=very unsatisfied, 2 =unsatisfied, 3=average, 4= satisfied and 5=very satisfied). Number of participants in each category was reported.

    Measured: Hour 6

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted30 Apr 2013 (estimated)
  2. Study startSep 2007
  3. Primary completionMay 2008
  4. Study completionMay 2008

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
1,059 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01843660
Sponsor's protocol ID
CR016117
Other IDs
TRAMAPPAI4035, TRAMAP-CHN-MA-02
Status last verified
Jun 2013
First submitted
26 Apr 2013
Last updated
26 Aug 2013
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Tramadol HCl-Paracetamol in people with Low Back Pain and Shoulder Pain, run by Xian-Janssen Pharmaceutical Ltd..

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 26 Aug 2013. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 26 Aug 2013). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Pain Intensity Score Based on Numeric Rating Scale (NRS) at Hour 0.5 (time frame: Hour 0.5). The study lists 12 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Aug 2013.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in